title: [Amiloride inhalation therapy in mucoviscidosis].
abstract: The defective regulation of the secretory chloride channel and the accelerated rate of sodium absorption in the airway epithelia of patients with cystic fibrosis (CF) contribute to the dehydration of airway secretions which is responsible for secondary damage in the respiratory tract. The sodium-blocker amiloride inhibits sodium absorption depending on the dosage of the drug. This effect is documented by means of measuring transepithelial potential difference which is decreased following to inhalative amiloride administration in CF patients. Clinical long term efficiency has been shown to be probable, but has to be confirmed. Investigation in this field is difficult, because there are some other important factors which influence viscosity of mucus. The use of amiloride can best be evaluated, if it is given immediately after birth. However, the answer to some important questions has to be found before.
authors.affiliation: Universitäts-Kinderklinik Giessen.
authors.forename: H
authors.initials: H
authors.lastname: Lindemann
mesh_terms: D000280:Administration, Inhalation; D000336:Aerosols; D000584:Amiloride / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D003550:Cystic Fibrosis / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D006801:Humans
chemical_list: D000336:Aerosols; D000584:Amiloride
vernacular_title: Amiloridinhalationstherapie bei Mukoviszidose.